Clinical Trial Update: Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA). [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial of MASCT (Multiple Antigen Specific Cell Therapy) for hepatocellular carcinoma after radical resection or radiofrequency ablation has been sus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• MASCT (Multiple Antigen Specific Cell Therapy)

Snippet

Sponsor: HRYZ Biotech Co. | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: SUSPENDED